MyoKardia

company

About

MyoKardia is a clinical-stage biopharmaceutical company that develops targeted therapies for the treatment of rare cardiovascular diseases.

  • 251 - 500

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$10M
Industries
Biopharma,Biotechnology,Health Care,Medical,Therapeutics
Founded date
Sep 1, 2012
Number Of Employee
251 - 500
Operating Status
Active

MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. The company's focus is on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It utilizes its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy and dilated cardiomyopathy.

The company was founded in 2012 and is headquartered in Brisbane, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$10M
MyoKardia has raised a total of $10M in funding over 2 rounds. Their latest funding was raised on Aug 22, 2014 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 22, 2014 Series Unknown $10M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
MyoKardia is funded by 1 investors. Sanofi are the most recent investors.
Investor Name Lead Investor Funding Round
Sanofi Series Unknown